Rennova Health reports expiration of ~403.8B shares of warrants, extends 101.35B Series B warrants to Dec 2025

Rennova Health, Inc.

Warrants to purchase ~403.8 billion shares (Series A, B, C) expired on March 21, 2024, reducing potential dilution.
Series B warrants for 101.35 billion shares extended from March 21, 2024 to December 31, 2025, subject to exercise conditions.
Exercise conditions require specified share volumes exercised by dates from April 2024 to August 2025; no cashless exercise counts.
CEO Seamus Lagan stated the expiration significantly reduces potential dilution and the extension preserves capital access if conditions permit.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Rennova Health, Inc. amended Series B Warrants with certain institutional holders (effective 2024-03-20).

Action: amendment
Counterparty: certain institutional holders
Effective: 2024-03-20

Exact text from the filing

On March 20, 2024, Rennova Health, Inc. (the “Company”) and certain institutional holders agreed that, with respect to Series B Warrants (originally issued on March 21, 2017), to acquire 101,350,000,000 shares of common stock, the termination date of such warrants would be extended from March 21, 2024 to December 31, 2025

View on SEC.gov

536 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001493152-24-011342

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.